CN109875986A - Medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out - Google Patents
Medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out Download PDFInfo
- Publication number
- CN109875986A CN109875986A CN201711273450.8A CN201711273450A CN109875986A CN 109875986 A CN109875986 A CN 109875986A CN 201711273450 A CN201711273450 A CN 201711273450A CN 109875986 A CN109875986 A CN 109875986A
- Authority
- CN
- China
- Prior art keywords
- dermatitis
- breaking
- terms
- cell membrane
- mast cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention relates to medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out, the application in terms of the drug of preparation prevention dermatitis breaking-out.Drug of the present invention is to achieve the purpose that local administration by oral cavity sucking, and compared with Formulations for systemic administration, dose is small, Small side effects, and effect is obvious.After patient's use of 50 dermatitis as caused by allergic constitution, arrive the previous moon in allergy seasons, start to suck drug of the present invention, it inhales twice, inhales two months daily, there are 45 patients all to break out without dermatitis in allergy seasons, there are 5 patients to have the symptom of slight expectoration, but no apparent dermatitis breaking-out sign, obvious effective rate are efficient up to 100% up to 90%.
Description
Technical field
The present invention relates to medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out
Background technique
Dermatitis caused by allergic constitution is usually seasonable, usually in the season at the beginning of spring and autumn late summer, patient
Often to the medicinal powder allergy of a certain plant in the two seasons, lead to allergic asthma or dermatitis, symptom can probably continue
One month or so.
Mast cell membrane stabilizer has used for many years in treatment dermatitis, and effect is fine, and the inhalant is not containing blissful special
Two kinds of ingredients of sieve and budesonide have synergistic effect in terms of the exacerbation for mitigating dermatitis by different binding modes.Two kinds at
The mechanism of action difference divided is as follows: budesonide: the budesonide for sucking recommended dose has the anti-inflammatory of glucocorticoid to lung
Effect can reduce dermatitis symptom, and resistance is slow, and sb.'s illness took a turn for the worse, and opposite side effect is fewer than systemic medication.Formoterol is a choosing
Selecting property beta-2-adrenoreceptor agonists have diastole bronchial smooth muscle to the patient for playing the role of Reversible airway obstruction.Branch
Tracheaectasy onset of action is rapid, works in 1-3 minutes after inhalation, and single dose can maintain 12 hours.In clinical test, cloth
Formoterol is added in desonide, dermatitis symptom and lung function can be improved, sb.'s illness took a turn for the worse for reduction.But this sucking is used now
Agent is all to reuse this kind of drug when dermatitis breaking-out to be treated, this just causes certain damage to the lung of patient,
If there is a kind of medicine can prevent dermatitis breaking-out that with regard to more preferable.
Summary of the invention
The technical problem to be solved in the present invention is to provide mast cell membrane stabilizers in terms of preparation prevents dermatitis breaking-out
The application of drug.
It is of the existing technology in order to solve the problems, such as, the technical solution adopted by the present invention is that:
Mast cell membrane stabilizer is preparing the drug for preventing the breaking-out of allergic dermatitis.
Advantage for present invention is with effect:
Drug of the present invention is to achieve the purpose that local administration by oral cavity sucking, and compared with Formulations for systemic administration, dose is small, and pair is made
With small, effect is obvious.After patient's use of 50 dermatitis as caused by allergic constitution, arrive in allergy seasons previous
Month, start to suck drug of the present invention, inhale twice, inhale two months daily, there are 45 patients all to break out without dermatitis in allergy seasons,
There are 5 patients to have the symptom of slight expectoration, but without apparent dermatitis breaking-out sign, up to 90%, effective percentage reaches obvious effective rate
100%.
Specific embodiment
Embodiment
Mast cell membrane stabilizer can be used for preventing the breaking-out of allergic dermatitis, and application method is: arrive in allergy seasons
The previous moon come start to suck mast cell membrane stabilizer, twice daily, the patient of Spring Festival allergy can inhale two months, right
This solar term of White Dew, which can be drawn onto, in the patient of autumn allergy can stop to inhale, and can thus prevent allergic dermatitis breaking-out.
Claims (1)
1. medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out, it is characterised in that in preparation prevention dermatitis hair
The application of the aspect of the drug of work.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711273450.8A CN109875986A (en) | 2017-12-06 | 2017-12-06 | Medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711273450.8A CN109875986A (en) | 2017-12-06 | 2017-12-06 | Medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109875986A true CN109875986A (en) | 2019-06-14 |
Family
ID=66923359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711273450.8A Pending CN109875986A (en) | 2017-12-06 | 2017-12-06 | Medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109875986A (en) |
-
2017
- 2017-12-06 CN CN201711273450.8A patent/CN109875986A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528474A5 (en) | ||
| WO2016111899A1 (en) | Methods and materials for treating lung disorders | |
| CN103301254B (en) | Antibacterial liquid used for nasopharyal meatus and preparation method thereof | |
| MY179794A (en) | Compound composition for inhalation used for treating asthma | |
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| US20070020194A1 (en) | Nasally administered appetite suppressant | |
| CN104800597A (en) | Traditional Chinese medicine composition for treating sphagitis | |
| CN109875986A (en) | Medical applications of the mast cell membrane stabilizer in terms of preventing dermatitis breaking-out | |
| CN105012487B (en) | Children's nose, which relaxes, leads to nasal drops | |
| CN105412118B (en) | Treat dyspneic Western medicine compound of acute and chronic and preparation method thereof | |
| TWI253930B (en) | Novel combination of loteprednol and beta2 adrenoceptor agonists | |
| EP3125876B1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| Chrystyn et al. | P154 Evaluation of Inhaler Technique Mastery for Budesonide Formoterol Spiromax® Compared with Symbicort Turbohaler® in Adult Patients with Asthma: Primary Results From the Easy Low Instruction Over Time [ELIOT] Study | |
| CN104274750B (en) | A kind of Chinese medicine composition for treating acute bronchitis, the infection of the upper respiratory tract | |
| CN1660256A (en) | Medication for treating cough caused by inflammation of upper respiratory tract | |
| CN105456240B (en) | Ambroxol albuterol aerosol | |
| CN105362226B (en) | The preparation method of ambroxol albuterol aerosol | |
| CN101991582A (en) | Pharmaceutical application of formoterol/budesonide powder for inhalation | |
| CN105326789B (en) | Ambroxol albuterol solution agent | |
| CN113633717B (en) | Electronic atomized liquid composition for nasal cavity care, application thereof and obtained care product | |
| CN109876142A (en) | The medical applications of β 2 receptor agonist | |
| CN107375422A (en) | Treatment part catarrh symptom liniment and preparation method thereof | |
| CN110179884B (en) | Tincture for infectious dermatitis and preparation method and application thereof | |
| CN105326790B (en) | The preparation method of ambroxol albuterol solution agent | |
| CN101991819A (en) | Plaster for treating stuffy nose and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190614 |
|
| WD01 | Invention patent application deemed withdrawn after publication |